Abstract
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
| Original language | English |
|---|---|
| Pages (from-to) | 11 |
| Number of pages | 422 |
| Journal | Thrombosis and haemostasis |
| Volume | 121 |
| Issue number | 04 |
| Early online date | 10 Nov 2020 |
| DOIs | |
| Publication status | E-pub ahead of print - 10 Nov 2020 |
Keywords
- antiplatelet therapy
- bleeding risk
- direct oral anticoagulants
- ischemic risk
- race
Fingerprint
Dive into the research topics of 'The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver